Autoimmune Diseases
From the Journals
ANA assay results differ widely in established lupus patients
Study results call into question the use of assays to determine trial eligibility and their role in clinical practice.
From the Journals
Majority of lupus patients lack eye exam around the start of hydroxychloroquine
Sociodemographic variation seen in Medicaid population study.
From the Journals
JAK inhibitors look good for severe alopecia areata treatment
Adolescents may benefit the most from this new therapy.
From the Journals
Predictors may help to spot risk for hydroxychloroquine nonadherence
A detailed look at the trajectories of patients who stop, continue, or never start the drug.
From the Journals
Cases link vitiligoid lichen sclerosus and darker skin
High-potency topical steroids and/or calcineurin inhibitors resolved symptoms in all cases, but depigmentation remained.
Conference Coverage
Neutrophilic urticarial dermatosis is usually misdiagnosed
GENEVA – This skin eruption is “underdiagnosed and overtreated” in SLE patients.
From the Journals
Rituximab tackles relapse of severe, difficult-to-treat pemphigus
Drug succeeds as a single, long-term maintenance therapy, with a better risk-to-benefit ratio than corticosteroids.
Conference Coverage
Novel oral orphan drug tames pemphigus
The Bruton tyrosine kinase inhibitor is also under study for other autoimmune diseases.
Conference Coverage
Nonadherence to lupus drugs may play a role in frequent hospitalization
SAN DIEGO – A higher risk for hospitalization also occurred among young, male, and African-American patients.
Conference Coverage
Blisibimod shows mixed results for lupus in phase 3 trial
SAN DIEGO – The drug did not meet its primary endpoint but was associated with steroid sparing, decreased urine protein, and improved biomarker...
Conference Coverage
Anabasum shows promise in treating skin-predominant dermatomyositis, systemic sclerosis
SAN DIEGO – The investigational drug met primary endpoints and showed good safety in two phase 2 studies.